This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
このページの翻訳は実験的なもので、現在開発中です。お待ちしております
TCRR 株式概要
TCR2 Therapeutics Inc., a clinical-stage cell therapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer.
TCR2 Therapeutics Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$1.48 |
| 52週高値 | US$3.88 |
| 52週安値 | US$0.82 |
| ベータ | 1.93 |
| 11ヶ月の変化 | -21.28% |
| 3ヶ月変化 | 22.31% |
| 1年変化 | -38.59% |
| 33年間の変化 | -88.47% |
| 5年間の変化 | n/a |
| IPOからの変化 | -90.18% |
最新ニュース
Recent updates
Here's Why TCR2 Therapeutics (NASDAQ:TCRR) Must Use Its Cash Wisely
Mar 08
Can TCR2 Therapeutics (NASDAQ:TCRR) Afford To Invest In Growth?
Nov 23TCR² Therapeutics: Betting On A Solid Reversal
Aug 18TCR2 Therapeutics GAAP EPS of -$0.82 misses by $0.02
Aug 08We Think TCR2 Therapeutics (NASDAQ:TCRR) Needs To Drive Business Growth Carefully
Jun 08We Think TCR2 Therapeutics (NASDAQ:TCRR) Can Afford To Drive Business Growth
Jan 11TCR2 Therapeutics: Trading Below Cash
Jan 06TCR2 Therapeutics: Trading Near Cash Value
Oct 12Is There An Opportunity With TCR2 Therapeutics Inc.'s (NASDAQ:TCRR) 26% Undervaluation?
Sep 02TCR2 Therapeutics - Promising Technology And Upside Potential
Jun 15Companies Like TCR2 Therapeutics (NASDAQ:TCRR) Are In A Position To Invest In Growth
Jun 04Who Has Been Selling TCR2 Therapeutics Inc. (NASDAQ:TCRR) Shares?
Feb 19
TCR2 Therapeutics (NASDAQ:TCRR) Is In A Good Position To Deliver On Growth Plans
Dec 28TCR2 Therapeutics share slumps 11%, announces response for Phase 1/2 Trial of TC-210
Dec 14TCR2 Therapeutics reports Q3 results
Nov 12TCR² Therapeutics teams up with ElevateBio to expand TC-210 manufacturing capacity
Nov 10株主還元
| TCRR | US Biotechs | US 市場 | |
|---|---|---|---|
| 7D | -6.3% | -3.0% | 0.9% |
| 1Y | -38.6% | 19.2% | 32.4% |
業界別リターン: TCRR underperformed the US Biotechs industry which returned 12.2% over the past year.
リターン対市場: TCRR underperformed the US Market which returned 2.4% over the past year.
価格変動
| TCRR volatility | |
|---|---|
| TCRR Average Weekly Movement | 12.5% |
| Biotechs Industry Average Movement | 10.0% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 3.2% |
安定した株価: TCRR's share price has been volatile over the past 3 months.
時間の経過による変動: TCRR's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 2015 | 58 | Garry Menzel | www.tcr2.com |
TCR2 Therapeutics Inc. 基礎のまとめ
| TCRR 基礎統計学 | |
|---|---|
| 時価総額 | US$58.11m |
| 収益（TTM） | -US$163.10m |
| 売上高(TTM) | n/a |
0.0x
P/Sレシオ-0.4x
PER（株価収益率TCRR は割高か？
公正価値と評価分析を参照収益と収入
| TCRR 損益計算書（TTM） | |
|---|---|
| 収益 | US$0 |
| 売上原価 | US$0 |
| 売上総利益 | US$0 |
| その他の費用 | US$163.10m |
| 収益 | -US$163.10m |
直近の収益報告
Mar 31, 2023
次回決算日
該当なし
| 一株当たり利益（EPS） | -4.15 |
| グロス・マージン | 0.00% |
| 純利益率 | 0.00% |
| 有利子負債／自己資本比率 | 0% |
TCRR の長期的なパフォーマンスは？
過去の実績と比較を見る